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Abstract
Background A chronic low-grade inflammatory profile (CLIP) is associated with sarcopenia in older adults. Protein and 
Vitamin (Vit)D have immune-modulatory potential, but evidence for effects of nutritional supplementation on CLIP is limited.
Aim To investigate whether 13 weeks of nutritional supplementation of VitD and leucine-enriched whey protein affected 
CLIP in subjects enrolled in the PROVIDE-study, as a secondary analysis.
Methods Sarcopenic adults (low skeletal muscle mass) aged ≥ 65 years with mobility limitations (Short Physical Perfor-
mance Battery 4–9) and a body mass index of 20–30 kg/m2 were randomly allocated to two daily servings of active (n = 137, 
including 20 g of whey protein, 3 g of leucine and 800 IU VitD) or isocaloric control product (n = 151) for a double-blind 
period of 13 weeks. At baseline and after 13 weeks, circulating interleukin (IL)-8, IL-1 receptor antagonist (RA), soluble 
tumor-necrosis-factor receptor (sTNFR)1, IL-6, high-sensitivity C-reactive protein, pre-albumin and 25-hydroxyvitamin(OH)
D were measured. Data-analysis included repeated measures analysis of covariance (corrected for dietary VitD intake) and 
linear regression.
Results IL-6 and IL-1Ra serum levels showed overall increases after 13 weeks (p = 0.006 and p < 0.001, respectively). For 
IL-6 a significant time × treatment interaction (p = 0.046) was observed, with no significant change over time in the active 
group (p = 0.155) compared to control (significant increase p = 0.012). IL-8 showed an overall significant decrease (p = 0.03). 
The change in pre-albumin was a significant predictor for changes in IL-6 after 13 weeks.
Conclusions We conclude that 13 weeks of nutritional supplementation with VitD and leucine-enriched whey protein may 
attenuate the progression of CLIP in older sarcopenic persons with mobility limitations.
Keywords Vitamin D · Leucine · Whey proteins · Dietary supplements · Cytokines · Aged
Introduction
Ageing is accompanied with a chronic low-grade inflam-
matory profile (CLIP) reflected by subtle increases in cir-
culating cytokines [1, 2]. CLIP has been associated with 
frailty in older adults [3, 4], increasing vulnerability to poor 
health outcomes such as disability, hospital admission and 
mortality [5]. Sarcopenia, a contributor to physical frailty, 
is a muscle failure disease that is caused by adverse muscle 
changes that accumulate over life [6]. A blunted response 
of muscle protein synthesis to nutrient intake is one of the 
greatest limitations to muscle preservation, which may be 
induced by inflammation among other factors [7].
Leucine, a branched-chain amino acid, can induce both 
anti-inflammatory and pro-inflammatory effects, probably 
depending on its circulating concentration [8–12]. Previous 
studies showed that the recommended amount of protein 
intake for older adults should be 1.0–1.5 g of proteins per 
kilogram body weight per day [13]. However, a majority of 
older adults does not reach these amounts of dietary protein 
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intake. Circulating vitamin (Vit)D is inversely related to 
IL-6 and CRP, and has an anti-inflammatory effect by con-
tributing to the regulation of immune cells [14, 15]. VitD 
deficiency is often present in older adults due to decreased 
UV-light exposure and reduced VitD synthesis and metabo-
lism [16]. Therefore, VitD supplementation is often indi-
cated [17].
Studies investigating the anti-inflammatory effect of 
nutritional supplementation show contradicting results 
[18–20]. In the PROVIDE study, 13 weeks of VitD and 
leucine-enriched whey protein supplementation improved 
muscle mass and lower extremity function among sarco-
penic older adults [21]. In addition, this study showed that 
sarcopenic participants with higher baseline circulating VitD 
concentrations and higher dietary protein intake obtained 
greater gains in muscle mass after 13 weeks intervention 
[22]. In the present sub-study, we investigated whether 
13 weeks of nutritional supplementation affected circulat-
ing inflammatory markers in older sarcopenic adults enrolled 
in the PROVIDE study.
Materials and methods
Participants
Detailed information on the PROVIDE study protocol was 
published previously [21] and can be found on https ://www.
trial regis ter.nl/trial reg with identifier: NTR2329. Subjects 
aged ≥ 65 years, with mild to moderate limitations in physi-
cal functioning (Short Physical Performance Battery (SPPB) 
score 4–9), with class I or II sarcopenia (skeletal muscle 
mass/BW × 100) < 37% in men and < 28% in women using 
bio-impedance analyses) [23], a body mass index (BMI) of 
20–30 kg/m2 and providing written informed consent were 
eligible for participation [21]. Eligible candidates were eval-
uated for in -and exclusion criteria during a screening visit as 
described elsewhere [21]. Briefly, 1240 participants from 6 
European countries (Belgium, Germany, Ireland, Italy, Swe-
den and the United Kingdom) were assessed for eligibility. 
380 were randomly allocated by Danone Nutricia Research 
to either the active (n = 184) or the control group (n = 196) 
via permuted block randomization (block size 4) stratified 
for SPPB categories 4–6 and 7–9 and study center. The ran-
domization sequence was computer-generated by a blinded 
statistician not involved in data collection or analysis. All 
investigators, study staff, and participants were blinded to 
group allocations (see Ref. [21] for details). 297 completed 
the 13 weeks intervention. In total, 78 from the 380 rand-
omized subjects terminated the RCT study early (38 in con-
trol and 40 in active group). From the 78 early terminators, 
45 subjects did not continue with the study because of an 
adverse event (AE), 2 subjects did not continue because of 
serious AE (assessed as not related to the study product), 15 
subjects withdrew their informed consent, 2 subjects were 
lost to follow-up, in 1 subject a protocol deviation occurred 
(the subject took calcium supplements) leading to study dis-
continuation and 13 subjects had another reason for discon-
tinuation. This sub-study is a secondary analysis based on 
subjects of whom inflammatory biomarkers were available 
(Fig. 1).
Intervention
Subjects either received the active product or the control 
product for a double-blind period of 13 weeks, as two 40-g 
sachets to be dissolved in 125 ml of water and consumed 
before breakfast and lunch, respectively. Per serving, the 
active product contained 20 g of whey protein, 3 g total 
leucine, and a mixture of carbohydrates and fat providing 
150 kcal per serving, 800 IU VitD and a mixture of fibres, 
minerals and vitamins. The isocaloric control product did 
not contain any protein or micronutrients; detailed compo-
sitions are shown in the Supplemental Table of the main 
PROVIDE publication [21].
Outcome measures
At the baseline visit (within 1 week after the screening 
visit), characteristics such as age, sex, BMI, ethnicity, living 
situation, medical history, cognitive function (mini-mental 
state examination) [24] and pre-existing conditions, use 
of nutritional supplements and medication were recorded. 
At baseline and after 7 and 13 weeks, subjects underwent 
assessments including handgrip strength, body composition, 
physical performance test and activity, dietary intake and 
blood sampling as described previously [21]. The Euro-
pean version of the Physical Activity Scale for the Elderly 
(PASE) was used to assess physical activity. Body composi-
tion was measured using dual energy X-ray absorptiometry 
(DXA, different models from Hologic, Bedford, USA; and 
Lunar, Fairfield, USA). Dietary VitD and protein intake 
were assessed by a 3-day dietary record, including two week 
days and one weekend day. Dietary records were checked 
for completeness with participants during study visits and 
additional information was obtained about unclear items 
or amounts. Total energy, macronutrient and micronutri-
ent intakes were calculated by the participating sites using 
country-specific dietary data entry systems and food com-
position tables.
After an overnight fast, serum samples were collected 
and frozen at – 80 °C until assayed for cytokines levels. 
IL-8 (ultrasensitive), IL-1RA and sTNFR1 were meas-
ured separately using commercially available ELISA kits 
(Lifetech, Carlsbad, CA), and IL-6 using an ultrasensi-
tive singleplex bead kit (Lifetech, USA) as described 
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previously [25]. Sensitivity levels were < 0.1 pg/ml (IL-
8), 4 pg/ml (IL-1RA), 50 pg/ml (sTNFR1) and < 0.05 pg/
ml (IL-6). For each participant the samples of both time 
points were analysed on the same plate to limit inter-assay 
variability. At baseline and 13 weeks, samples for deter-
mination of cytokines were available from respectively 
365 and 288 subjects (Fig. 1). Baseline characteristics 
of subjects with missing data for cytokines were similar 
to those who were included in the analyses, except for 
female subjects with missing data in whom the PASE was 
significantly lower (47.61 ± 31.36 versus 99.96 ± 67.21, 
p < 0.001).
At baseline, and after 7 and 13 weeks, CRP, pre-albu-
min and 25-hydroxyvitamin(OH)D were determined by 
the central PROVIDE laboratory as described elsewhere 
[21, 22]. For these analyses, several samples were miss-
ing at baseline (n = 3 out of 365), 7 weeks (n = 10 out of 
288) and 13 weeks (n = 17 out of 288). For 31 (out of 288) 
participants, no information was available for VitD intake 
throughout the study.
Statistical analyses
Statistical analyses were performed in IBM SPSS v25.0.0.0 
(SPSS Inc, Illinois, USA). Because of non-normal distribu-
tion (Kolmogorov–Smirnov Goodness of Fit test p < 0.05), 
all inflammatory markers were log (10)-transformed to 
reduce skewness and back transformed for data presentation 
(Supplementary Table 1). Baseline between group differ-
ences were analysed by unpaired t tests. Pearson correlations 
were computed between baseline inflammatory markers and 
other baseline outcomes.
Changes in cytokines over time were analysed with 
repeated-measures ANCOVA using time as within subject’s 
factor and intervention (active versus control product) group 
as between subject’s factor. Since dietary intake of VitD and 
protein might interfere with the nutritional supplement, the 
mean dietary intake of these components (average of intake 
measured at baseline, 7 weeks and 13 weeks) were entered in 
the models as covariates. We also verified whether other rel-
evant factors including fat mass, NSAID use, SPPB, PASE, 
Fig. 1  Flow chart
Assessed for eligibility
n=1240
Randomized to active product
n=184
included in baseline analyses
n=177
Included in analyses at 13 weeks
n= 137
40 lost to follow up:
23 adverse events
1 serious adverse event
10 withdrew consent
1 could not be located
5 other reasons
Missing inflammatory 
parameters at baseline n= 7
Randomized to control product
n=196
Included in baseline analyses
n=188
included in analyses at 13 weeks
n= 151
37 lost to follow up:
22 adverse events
1 serious adverse event
5 withdrew consent
1 could not be located
9 other reasons
Missing inflammatory parameters at 
baseline n= 8
860 not included:
109 non-sarcopenic according to BIA
534 SPPB out of range
98 BMI out of range
12 psychiatric condition
6 specific medication use
8 taking VitD and/or calcium supplements
30 medical condition prohibiting participation
36 refused participation
27 other
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sex, and baseline 25(OH)D were significant covariates in 
the analyses. Since only mean dietary VitD intake was a 
significant factor, this was finally retained as covariate. In 
addition, these analyses were repeated including only par-
ticipants with CRP ≤ 10 mg/Llthroughout the entire study 
to eliminate potential bias due to acute inflammatory condi-
tions (reflected by CRP-value > 10 mg/l [26]).
Next, linear regression was used to appraise the pro-
portional contribution of changes in circulating 25(OH)D 
and protein (reflected by circulating pre-albumin [27]) to 
the changes in those cytokines for which a significant time 
× treatment interaction was found. The change in cytokine 
level was used as dependent variable and mean dietary 
intake of VitD and protein, as well as change in pre-albumin 
and circulating 25(OH)D values were used as predictors. 
Significance was set at p < 0.05.
Results
There were no significant differences between both groups 
at baseline (Table 1). Sex differences in body composition 
and muscle strength were reported previously [21] and were 
in line with the expectations.
As shown in Table 2, baseline cytokines and dietary pro-
tein intake were not significantly correlated. Higher dietary 
VitD intake and circulatory 25(OH)D were significantly 
related to lower IL-8. Baseline SPPB and PASE were nega-
tively correlated with baseline cytokines. Fat mass corre-
lated negatively with IL-8 and positively with CRP.
IL-6 and IL-1Ra showed an overall significant increase 
after 13  weeks (p = 0.006 and p < 0.001, respectively; 
Fig. 2). For IL-6 a significant time × treatment interac-
tion (p = 0.046) showed that the increase was attenuated 
in the active (no increase: 1.95 ± 1.09 to 2.17 ± 1.08 pg/
ml; p = 0.155) compared to control (significant increase: 
1.96 ± 1.09 to 2.56 ± 1.07 pg/ml; p = 0.012) group. IL-8 
showed an overall significant decrease (p = 0.03), but there 
was no significant time × treatment interaction (p = 0.24). 
Back transformed data on changes over time can be found 
in Supplementary Table 1.
To eliminate potential bias due to acute inflammatory 
conditions during the study, we identified all participants 
who showed a CRP-value > 10 mg/l—as an indicator for 
an active inflammatory condition [26]—at any time point 
during the study. In participants with baseline CRP ≤ 10 
mg/l, 14 persons acquired an inflammatory profile (i.e. 
CRP-value > 10 mg/l) after 7 weeks intervention (10 in the 
active and 4 in the control group, p = 0.057). At 13 weeks, 
three participants retained an inflammatory profile (two in 
the active and one in the control group, p = 0.913). For par-
ticipants showing no inflammation in the previous period, 
13 acquired an inflammatory profile at week 13 (6 in the 
active and 7 in the control group, p = 0.956). When including 
only participants with CRP ≤ 10 mg/l throughout the entire 
study (n = 227; active n = 103 and control n = 124; subjects 
with missing data for CRP were also excluded), comparable 
results, though more pronounced, were found (see Supple-
mentary Fig. 1).
Finally, we computed a linear regression model to 
appraise the proportional association of changes in circu-
lating 25(OH)D and pre-albumin to the changes in IL-6 
(Table 3). Only the change in pre-albumin was significantly 
associated with changes in IL-6 after 13 weeks.
Discussion
We assessed the effect of a 13-week VitD and leucine-
enriched whey protein oral nutritional intervention on CLIP 
in sarcopenic older adults with mobility limitations. We 
found an overall increase in CLIP (demonstrated by IL-6 and 
IL-1RA), which was significantly attenuated in the active 
group compared to control for IL-6. When excluding partici-
pants who might have experienced pathologic acute inflam-
mation during the study (based on CRP-values > 10 mg/l), 
the anti-inflammatory effects of the active intervention 
remained significant, and was even more pronounced.
CLIP is a well-known phenomenon in the aged [1, 
28–30]. Contributing factors include immunosenescence, 
lack of physical activity, decline of sex hormones and 
increase in adipose tissue [2, 31–34]. The exact kinetics of 
CLIP are not well described in the literature. However, CLIP 
is more pronounced in (pre)frail older adults and/or older 
subjects with chronic diseases [1, 4, 35–37]. Given the spe-
cific profile of our participants with low muscle mass and 
mobility limitations, it can be expected that CLIP would 
have progressed more rapidly than expected in a group of 
healthier older persons. The IL-6 levels in our participants 
(median = 1.97 pg/ml, P25–P75 = [1.19–2.96]) correspond 
to the levels for CLIP (2.13 pg/ml [1.37–4.23]) as recently 
reviewed [30]. The cross-sectional data reviewed by Calder 
et al. [30] suggest mean differences of about 0.7 pg/ml for 
log IL-6 between young and older adults. In this context 
the difference in change in IL-6 between active and control 
group that we observed might be of clinical relevance.
Our findings are in line with a recently published RCT 
investigating the additional effect of a combined VitD 
and whey protein oral nutritional supplement on exercise-
induced changes in CRP in sarcopenic older persons [38]. 
They reported a significant time × treatment effect after 
12 weeks intervention (p = 0.04) characterized by a ten-
dency for CRP to increase in the placebo group (+ 4.4 mg/l, 
p = 0.06) which was attenuated in the intervention group 
(− 1.9 mg/l, p = 0.33) [38]. However, these authors did not 
quantify other biomarkers of CLIP.
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Table 2  Associations between baseline inflammatory parameters, and vitamin D and protein status and intake, functional status, and fat mass
Pearson correlation coefficients **p < 0.01, * p < 0.05
VitD intake (µg/
day)
25(OH)D 
(nmol/l)
Protein intake (g/
kg body weight)
Pre-albumin 
(g/l)
SPPB (score 
0–9)
Fat mass (kg) PASE (score 
0–793)
Log_sTNFR1 
(ng/ml)
− 0.09 − 0.07 0.02 − 0.065 − 0.27** − 0.05 − 0.25**
Log_IL8 (pg/ml) − 0.19** − 0.12* 0.05 − 0.136** − 0.20** − 0.19** − 0.16**
Log_IL1RA (pg/
ml)
0.07 − 0.06 − 0.07 − 0.083 − 0.10 0.07 − 0.11*
Log_IL6 (pg/ml) − 0.04 − 0.09 0.04 − 0.173** − 0.14** 0.01 − 0.15**
Log_CRP (mg/l) − 0.08 − 0.05 − 0.07 − 0.166** − 0.14** 0.18** − 0.13*
Fig. 2  Effects of active versus control intervention on inflammatory 
markers. a IL-6, b sTNFR1, c IL-8, d IL1Ra, e CRP bars represent 
mean values  ±  1SD corrected for mean dietary VitD intake as a 
covariate. Repeated measures ANCOVA; †significantly different from 
baseline p < 0.05
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VitD and protein supplementation can reduce CLIP 
through several pathways. VitD inhibits T-cell proliferation, 
inhibiting Th1 and Th17 pro-inflammatory responses and 
stimulating Th2 response, resulting in a decreased inflam-
matory profile [15, 39]. Inflammatory cells can convert VitD 
into calcitriol, which can itself regulate the cytokines by 
blocking NF-kß p65 activation (by upregulation of ikBa) 
which in its turn can inhibit differentiation of B-cells to 
plasma cells [40]. In dendritic cells, VitD3 downregulates 
the expression of pro-inflammatory cytokines, inhibits dif-
ferentiation of plasma cells and upregulates expression 
of anti-inflammatory cytokines (such as IL-10) as well 
as inflammation-inhibiting molecules such as ILT-3 [41]. 
Dietary proteins are crucial for muscle anabolism and con-
sidered to play a major role in countering sarcopenia and 
CLIP [42]. Amino acids such as leucine have strong ana-
bolic effects and stimulate intramuscular protein synthesis 
via upregulation of the mTOR pathway, which also reduces 
protein breakdown and can induce anti-inflammatory effects 
[8, 43]. Also β-hydroxy β-methylbutyrate, a metabolite of 
leucine, has anti-inflammatory effects in older persons [44].
As both VitD and protein—as main components of the 
nutritional supplement—can have anti-inflammatory effects, 
linear regression analysis was used to appraise the propor-
tional contribution of changes in circulating 25(OH)D and 
protein (reflected by circulating pre-albumin) to the changes 
in IL-6. Our results point towards the effects of the protein 
component of the nutritional supplementation (reflected by 
the changes in circulating pre-albumin) as significantly asso-
ciated with the attenuation in IL-6 increase. Although many 
studies investigated the effect of nutritional supplementation 
on physical outcomes, very few investigated the effects on 
inflammation in older adults [45, 46]. Most studies did not 
find any effect of VitD on inflammation [47, 48]. Studies 
reporting significant effects were contradictory and remained 
inconclusive (see Ref. [49] for review).
Our findings regarding IL-8 are in line with those 
reported by Yusupov et al. who found that IL-8 decreased 
significantly after 12  weeks of VitD supplementation 
(− 48%, p < 0.001), which was comparable to the decrease 
in the control group (− 33%, p = 0.02) [50]. Nakashyan 
et al. recently performed a study on constitutive and IL-
1ß-stimulated human gingival fibroblast, where they ana-
lysed the effect of VitD on levels of IL-6. In constitutive 
fibroblast, IL-6 production decreased by ~ 50%. When cells 
were stimulated with IL-1ß, the effects on IL-6 depended on 
the time when the cells were exposed to VitD. The longer 
the time in between the IL-1ß stimulus and the VitD expo-
sure, the smaller the effect observed [51]. Considering the 
inflammatory effects of IL-1ß, this is comparable to the 
results obtained in our analyses, where a time effect was 
seen when all participants were included. When participants 
who acquired an inflammatory profile (i.e. CRP > 10 mg/l) 
were excluded from our analyses, the effects on IL-6 were 
more pronounced. In our study, the levels of circulating 
sTNFR1 were not related to protein or VitD, and did not 
show changes over time. Similarly, Vita et al. found no cor-
relation between VitD and sTNFR1 or IL-1Ra in older adults 
[14].
The strengths of this study are the double-blinded 
randomized and controlled design and the large sample 
size. Also, the analyses with high-sensitivity ELISA kits 
allowed to detect small changes in inflammatory mark-
ers. However, the results should be interpreted cautiously, 
since the nutritional supplement contained other com-
pounds besides VitD, leucine and whey proteins which 
might have influenced the anti-inflammatory effects. As 
reported earlier [21, 22], the active product contained 
micronutrients, including also 2.2  g zinc per serving 
whereas the iso-caloric control product contained only 
carbohydrates and fat. Dietary zinc intake as well as circu-
lating zinc levels are inversely related to IL-6, TNF-α and 
CRP [52]. In addition, Bao et al. found that IL-6 decreased 
significantly after 6 months of zinc supplementation in 40 
older adults [53]. Unfortunately, we have no data regarding 
zinc status in our participants. Another potential limitation 
Table 3  Explanatory regression 
analysis for changes in IL-6 
after 13-weeks
A multiple linear regression model was computed with change in Log_IL6 as dependent variable, and 
mean dietary intake of VitD and protein, as well as change in pre-albumin and circulating 25(OH)D values 
as predictors. Only the change in circulating pre-albumin was significantly associated with changes in Log_
IL-6 after 13 weeks; in fact, higher increase in circulating pre-albumin was associated with lower changes 
in Log_IL6 (B coefficient = − 1.685, p = 0.002), independently from the other factors entered in the model
R² = 0.049, p = 0.015 B coefficients p value 95.0% Confidence interval for B
Lower bound Upper bound
Change in Log_IL6
 (Constant) 0.114 0.099 − 0.022 0.250
 Dietary VitD intake − 0.002 0.812 − 0.016 0.013
 Dietary protein intake < 0.001 0.830 − 0.002 0.002
 Change in circulating pre-albumin − 1.685 0.002 − 2.766 − 0.604
 Change in circulating 25(OH)D − 0.002 0.105 − 0.004 < 0.001
852 Aging Clinical and Experimental Research (2019) 31:845–854
1 3
is that the dose of the oral nutritional supplement might 
not have been sufficiently high to obtain optimal effects. 
In the study performed by Azizieh et al. participants with 
deficient VitD levels and high CRP showed higher levels 
of pro-inflammatory cytokines compared to participants 
with sufficient VitD levels [54]. In our study, the supple-
mentation dose was not tailored according to, e.g. baseline 
25(OH)D status or nutritional protein intake. On the other 
hand, we used dietary VitD intake as a covariable in our 
analyses, and the influence of other potential confound-
ers such as dietary protein intake, physical functioning, 
physical activity and NSAID use has been verified. In this 
study we used pre-albumin level as a surrogate marker for 
the protein-related nutritional status. However, since pre-
albumin level can—at least in acute inflammatory condi-
tions—be influenced by ongoing inflammation [55, 56], 
we cannot exclude that this might have affected our results. 
Therefore, the role of the proteins in the supplement on the 
attenuation of CLIP in our study needs to be interpreted 
with caution. 25% of the randomized subjects were lost to 
follow-up or showed missing data, which is relatively high 
but acceptable for a clinical trial in older patients with 
mobility limitations. Finally, as this was a multi-center 
study, environmental factors such as season of the year or 
exposure to sunlight—which is a source of VitD—might 
have influenced the results [57].
Conclusions
Based on the results of our study, we conclude that 
13 weeks of nutritional supplementation with VitD and 
leucine-enriched whey protein may attenuate the progres-
sion of chronic low-grade inflammation in older sarco-
penic persons with mobility limitations. Our results can 
be of clinical significance since chronic low-grade inflam-
mation is a major contributor to the progression of frailty 
and sarcopenia.
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